NCT06416930View on ClinicalTrials.gov

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

June 20, 2027

Study Completion Date

June 20, 2029

Conditions
Pleural Mesothelioma
Interventions
DRUG

Cadonilimab Combined with chemotherapy

Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.

Sponsors

Collaborators (1)

Akesobio
All Listed Sponsors
collaborator

Akesobio

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06416930 - Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | Biotech Hunter | Biotech Hunter